New: Introducing the Finviz Crypto Map

Arcutis Biotherapeutics, Inc.

Contributing Author

Recent Articles by Arcutis Biotherapeutics, Inc.

Jul-03	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Jun-26	Arcutis' ZORYVE (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis ARQT GlobeNewswire
Jun-10	Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis ARQT GlobeNewswire
Jun-06	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Jun-06	Arcutis to Present New Long-Term Results of ZORYVE (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference ARQT GlobeNewswire
May-29	Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference ARQT GlobeNewswire
May-22	Arcutis' ZORYVE (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older ARQT GlobeNewswire
May-15	New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice ARQT GlobeNewswire
May-07	Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology ARQT GlobeNewswire
May-06	Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update ARQT GlobeNewswire
May-02	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire

Affiliate • Advertise • Theme Settings • Contact • Blog • Help • Privacy • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.